# Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

> **NCT02782624** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT02782624
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2016-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782624, "Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT02782624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*